CERYVYN THERAPEUTICS LIMITED
ASX:CYVPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 87.4% of what they think they own, once every option and right converts.
Options/rights overhang 14% of shares; recent proposed issue, issue not on record; since relisting as CYV; prior history under OPT not included
CERYVYN THERAPEUTICS LIMITED has traded as CYV only since July 2026 after renaming from OPT; all disclosed figures cover only the period since the rename. No share-issuance (Appendix 2A) filings are on record in that window, and no new share issuances have been lodged since January 2024. The company has not raised capital through any cash placement, rights issue or share purchase plan in the 24-month window. Options and rights could convert into 197M new shares, a 14.4% overhang, with none in the money and the nearest expiry in November 2029. It has more than 4 quarters of funding at the recent spend rate. No proposed securities issues are pending.
Quick answers · 2
How much cash does CYV have?
In its quarterly cash report for the quarter ended 30 June 2026, Ceryvyn Therapeutics reported $30.0M of cash and estimated 26.8 quarters of funding available at its current rate of spending. That is the company's own estimate.
When do CYV's options expire?
Unexercised options and rights equal 14.4% of Ceryvyn Therapeutics's shares on issue; the nearest expiry is Nov 2029.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 4 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 24 Sept 2026 | 3G · unquoted | CYV : ORDINARY FULLY PAID | 1.37B | Appendix 3G |
| 14 Sept 2026 | 3G · unquoted | CYV : ORDINARY FULLY PAID | 1.37B | Appendix 3G |
| 21 Aug 2026 | 3G · unquoted | CYV : ORDINARY FULLY PAID | 1.37B | Appendix 3G |
| 13 July 2026 | 3H · cancellation | CYV : ORDINARY FULLY PAID | 1.37B | Appendix 3H |
Securities on issue over time
Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.
Capital raises
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
- Price-triggered182.4M · 13.3% of sharesOptions and warrants — they convert when the share price clears their exercise price.At least 164.9M of it states no exercise price — that much cannot be called in or out of the money.
- Condition-triggered2.9M · 0.2% of sharesPerformance and incentive rights — they convert when a hurdle is met, not at a price, and can lapse to nothing.
- Not classified11.7M · 0.9% of sharesThe filing’s description does not identify the instrument.
Exercise price on record: 17.5M priced, 179.5M where the filing never states one. A security with no exercise price is never counted in the money — nothing is paid to convert it, so there is no price for it to be above.
Each figure is the filing’s own count of securities, not a share count — a 2A never states what one security converts into.
An exercise price is on record for only 8.9% of this supply, so what is in the money today is not a measurement — the tile above reads “—” for that reason. Of the priced supply, 0 is in the money at $0.010 today. No more priced supply until 1.25× today’s price, which takes it to 10.2M (0.7% of shares).
- Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
- 179.5M (91.1% of the supply above) states no exercise price at all. It cannot be called in or out of the money at any price, which is why it is hatched rather than plotted.
- 277k more carries an exercise price above ten times today’s — off the right of this axis, and in every total on this page.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| CYVAF | Options | Price-triggered | $0.020 | 11 Nov 2029 | 7.0M | Filing |
| CYVAE | Options | Price-triggered | $0.011 | 20 Aug 2031 | 7.2M | Filing |
| — | Options | Price-triggered | $0.011 | 21 Sept 2031 | 3.0M | Filing |
| CYVAL | Options | Price-triggered | $3.03 | 19 Feb 2034 | 250k | Filing |
| CYVAA | Options | Price-triggered | $4.14 | 31 Mar 2034 | 27k | Filing |
| CYVAD | Performance rights | Condition-triggered | — | — | 2.9M | Filing |
| CYVAC | — | Not classified | — | — | 11.7M | Filing |
| CYVAB | Options | Price-triggered, no exercise price stated | — | — | 164.9M | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.
Director dealings
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.